New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

Life Sciences

Volumn 72, Issue 21, 2003, Pages 2305-2320

  Schally, Andrew V ^a   Nagy, Attila ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Breast cancer therapy; Lung cancer therapy; Ovarian cancer therapy; Prostate cancer therapy; Renal cancer therapy; Targeted cytotoxic analogs

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 215; BOMBESIN DERIVATIVE; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; METHOTREXATE; OCTREOTIDE; PENTETREOTIDE; RC 3095; RC 3940 2; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; BONE MARROW TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CELL DAMAGE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; ENDOCRINE TUMOR; EXPERIMENTAL NEOPLASM; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG SMALL CELL CANCER; METASTASIS; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PROSTATE CANCER; SHORT SURVEY; SIDE EFFECT; TARGET CELL;

EID: 0037432496     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00113-9     Document Type: Short Survey

References (67)

1. Arencibia J.M., Bajo A.M., Schally A.V., Krupa M., Chatzistamou I., Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti Cancer Drugs. 13:2002;949-956.
2. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T.J., Pless J. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences. 31:1982;1133-1140.
3. Benali N., Cordelier P., Calise D., Pagés P., Rochaix P., Nagy A., Estéve J.P., Pour P.M., Schally A.V., Vaysse N., Susini C., Buscail L. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proceedings of the National Academies of Science USA. 97:2000;9180-9185.
4. Buscail L., Saint-Laurent N., Chastre E., Vaillant J.C., Gespach C., Capella G., Kalthoff H., Lluis F., Vaysse N., Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Research. 56:1996;1823-1827.
5. 2 or its derivatives. Proceedings of the National Academy of Sciences USA. 91:1994;12664-12668.
6. Cai R.-Z., Szoke B., Lu R., Fu D., Redding T.W., Schally A.V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proceedings of the National Academy of Sciences USA. 83:1986;1896-1900.
7. Chabner B. Cancer chemotherapy. Principles and practice. 1990;J.B. Lippincott, Philadelphia.
8. Chatzistamou I., Schally A.V., Nagy A., Armatis P., Szepeshazi K., Halmos G. Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Clinical Cancer Research. 6:2000;4158-4165.
9. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., Minna J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 316:1985;823-826.
10. Dondi D., Limonta P., Moretti R.M., Marelli M.M., Garattini E., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Research. 54:1994;4091-4095.
11. Emons G., Ortmann O., Becker M., Irmer G., Springer B., Laun R., Holzel F., Schulz K.-D., Schally A.V. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Research. 53:1993;5439-5446.
12. Emons G., Schally A.V. The Use of Luteinizing Hormone-Releasing Hormone Agonists and Antagonists in Gynecological Cancers. Human Reproduction. 9:1994;1364-1379.
13. Fekete M., Wittliff J.L., Schally A.V. Characteristics and distribution of receptors for peptide hormones and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis. 3:1989;137-141.
14. Gründker C., Völker P., Griesinger F., Ramaswamy A., Nagy A., Schally A.V., Emons G. Antitumor effects of cytotoxic LHRH analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. American Journal of Obstetrics and Gynecology. 187:2002;528-537.
15. Halmos G., Arenciba J.M., Schally A.V., Davis R., Bostwick D.G. High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers. Journal of Urology. 163:2000;623-629.
16. Halmos G., Nagy A., Lamharzi N., Schally A.V. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Letters. 136:1999;129-136.
17. Halmos G., Schally A.V., Sun B., Davis R., Bostwick D.G., Plonowski A. High expression of somatostatin receptors and ribonucleic acid for its receptor subtypes in organ- confined and locally advanced human prostate cancers. Journal of Clinical Endocrinology and Metabolism. 85:2000;2564-2571.
18. Halmos G., Sun B., Schally A.V., Hebert F., Nagy A. Human ovarian cancers express somatostatin receptors. Journal of Clinical Endocrinology and Metabolism. 85:2000;3509-3512.
19. Irmer G., Bürger C., Muller R., Ortmann O., Peter U., Kakar S.S., Neill J.D., Schulz K.D., Emons G. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Research. 55:1995;817-822.
20. Jungwirth A., Schally A.V., Nagy A., Pinski J., Groot K., Galvan G., Szepeshazi K., Halmos G. Regression of Rat Dunning R-3327-H Prostate Carcinoma by Treatment with Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Containing 2-Pyrrolinodoxorubicin. International Journal of Oncology. 10:1997;877-884.
21. Kahan Z., Nagy A., Schally A.V., Halmos G., Arencibia J.M., Groot K. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer. 85:1999;2608-2615.
22. Kahan Z., Nagy A., Schally A.V., Halmos G., Arencibia J.M., Groot K. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Research and Treatment. 59:2000;255-262.
23. Kahan Z., Nagy A., Schally A.V., Hebert F., Sun B., Groot K., Halmos G. Inhibition of growth of MX-1, MCF-7, MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. International Journal of Cancer. 82:1999;592-598.
24. Karten M.J., Rivier J.E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Reviews. 7:1986;44-66.
25. Kiaris H., Schally A.V., Nagy A., Sun B., Armatis P., Szepeshazi K. Targeted Cytotoxic analog of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. British Journal of Cancer. 81:1999;966-971.
26. Kiaris H., Schally A.V., Nagy A., Sun B., Szepeshazi K., Halmos G. Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clinical Cancer Research. 6:2000;709-717.
27. Kiaris H., Schally A.V., Nagy A., Szepeshazi K., Hebert F., Halmos G. A targeted cytotoxic somatostatin (SST) analogue AN-238 inhibits the growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. European Journal of Cancer. 37:2001;620-628.
28. Klijn J.G., Beex L.V., Mauriac L., van Zijl J.A., Veyret C., Wildiers J., Jassem J., Piccart M., Burghouts J., Becquart D., Seynaeve C., Mignolet F., Duchateau L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. Journal of the National Cancer Institute. 92:2000;903-911.
29. Koppan M., Nagy A., Schally A.V., Arencibia J.M., Plonowski A., Halmos G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits the growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Research. 58:1998;4132-4137.
30. Koppan M., Nagy A., Schally A.V., Plonowski A., Halmos G., Arencibia J.M., Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 38:1999;151-158.
31. Kovacs M., Schally A.V., Csernus B., Busto R., Rekasi Z., Nagy A. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. Journal of Neuroendocrinology. 14:2002;5-13.
32. Kovacs M., Schally A.V., Nagy A., Koppan M., Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences USA. 94:1997;1420-1425.
33. 3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine. 20:1993;716-731.
34. Lamberts S.W., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews. 12:1991;450-482.
35. Limonta P., Dondi D., Moretti R.M., Maggi R., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism. 75:1992;207-212.
36. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research. 59:1999;1152-1159.
37. Miyazaki M., Nagy A., Schally A.V., Lamharzi N., Halmos G., Szepeshazi K., Groot K., Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Journal of the National Cancer Institute. 89:1997;1803-1809.
38. Miyazaki M., Schally A.V., Nagy A., Lamharzi N., Halmos G., Szepeshazi K., Armatis P. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. American Journal of Obstetrics and Gynecology. 180:1999;1095-1103.
39. Nagy A., Armatis P., Cai R.-Z., Szepeshazi K., Halmos G., Schally A.V. Design, synthesis and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences USA. 94:1997;652-656.
40. Nagy A., Plonowski A., Schally A.V. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin-14-O-hemiglutarate in mouse and human serum in vitro; implications for the design of preclinical studies. Proceedings of the National Academy of Sciences USA. 97:2000;829-834.
41. Nagy A., Schally A.V. Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers. Drugs of the Future. 26:2001;261-270.
42. Nagy A., Schally A.V. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH); A new approach to targeted chemotherapy. Drugs of the Future. 27:2002;359-370.
43. Nagy A., Schally A.V., Armatis P., Szepeshazi K., Halmos G., Kovacs M., Zarandi M., Groot K., Miyazaki M., Jungwirth A., Horvath J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proceedings of the National Academy of Sciences USA. 93:1996;7269-7273.
44. Nagy A., Schally A.V., Halmos G., Armatis P., Cai R.-Z., Csernus V., Kovacs M., Koppan M., Szepeshazi K., Kahan Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative 2-pyrrolinodoxonubicin. Proceedings of the National Academy of Sciences USA. 95:1998;1794-1799.
45. Patel Y.C. Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigation. 20:1997;348-367.
46. Plonowski A., Nagy A., Schally A.V., Sun B., Groot K., Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215. International Journal of Cancer. 88:2000;652-657.
47. Plonowski A., Schally A.V., Koppan M., Nagy A., Arencibia J.M., Csernus B., Halmos G. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer. 92:2001;1168-1176.
48. Plonowski A., Schally A.V., Nagy A., Groot K., Krupa M., Navone N.M., Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Letters. 176:2002;57-63.
49. Plonowski A., Schally A.V., Nagy A., Kiaris H., Hebert F., Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analog of somatostatin AN-238. Cancer Research. 60:2000;2996-3001.
50. Plonowski A., Schally A.V., Nagy A., Sun B., Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Research. 59:1999;1947-1953.
51. Radulovic S., Nagy A., Szoke B., Schally A.V. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA-PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Letters. 62:1992;263-271.
52. Reubi J.C., Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Research. 52:1992;6074-6078.
53. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., Halmos G. Hypothalamic hormones and cancer. Frontiers in Neuroendocrinology. 22:2001;248-291.
54. Schally A.V., Comaru-Schally A.M., Plonowski A., Nagy A., Halmos G., Rekasi Z. Peptide analogs in the Therapy of Prostate Cancer. The Prostate. 5:2000;158-166.
55. Schally A.V., Halmos G., Rekasi Z., Arencibia J.M. The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. Devroey P. Infertility and Reproductive Medicine Clinics of North America. GnRH Analogues. vol. 12:2001;17-44.
56. Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. European Journal of Endocrinology. 141:1999;1-14.
57. Schally A.V. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. Peptides. 20:1999;1247-1262.
58. Schally A.V. Oncological applications of somatostatin analogs. Cancer Research. 48:1998;6977-6985.
59. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L., Luketich J.D., Siegfried J.M. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. Journal of the National Cancer Institute. 92:2000;24-33.
60. 6] luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. International Journal of Oncology. 12:1998;489-498.
61. 6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Research. 50:1990;1841-1846.
62. Sun B., Halmos G., Schally A.V., Wang X., Martinez M. The presence of receptors for bombesin/gastrin-releasing peptide and mRNA for 3 receptor subtypes in human prostate cancers. The Prostate. 42:2000;295-303.
63. Sunday M.E., Kaplan L.M., Motoyama E., Chin W.W., Spindel E.R. Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Laboratory Investigation. 59:1998;5-24.
64. Szepeshazi K., Schally A.V., Halmos G., Armatis P., Hebert F., Sun B., Feil A., Kiaris H., Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Research. 62:2002;781-788.
65. Szepeshazi K., Schally A.V., Halmos G., Sun B., Hebert F., Csernus B., Nagy A. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer. Clinical Cancer Research. 7:2001;2854-2861.
66. Szepeshazi K., Schally A.V., Nagy A. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Research and Treatment. 56:1999;267-276.
67. Szereday Z., Schally A.V., Nagy A., Plonowski A., Bajo A.M., Halmos G., Szepeshazi K., Groot K. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue. AN-215 British Journal of Cancer. 86:2002;1322-1327.